Propofol-Associated Hypertriglyceridemia in Coronavirus Disease 2019 Versus Noncoronavirus Disease 2019 Acute Respiratory Distress Syndrome
Authors:
Open Access
- 16 December 2020
- journal article
- case report
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 2 (12) , e0303
Abstract
Objectives: To characterize the incidence and characteristics of propofol-associated hypertriglyceridemia in coronavirus disease 2019 versus noncoronavirus disease 2019 acute respiratory distress syndrome. Design: Single-center prospective, observational cohort study. Setting: Medical ICU and regional infectious containment unit. Patients: Patients with acute respiratory distress syndrome admitted from April 7, 2020, to May 15, 2020, requiring continuous propofol administration. Interventions: None. Measurements and Main Results: Of 50 patients enrolled, 54% had coronavirus disease 2019 acute respiratory distress syndrome. Median Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores were 35.5 (interquartile range, 30.2–41) and 8 (interquartile range, 6–9). Pao 2/Fio 2 ratio was 130.5 (interquartile range, 94.5–193.8). Patients with coronavirus disease 2019-associated acute respiratory distress syndrome experienced a higher rate of hypertriglyceridemia (triglyceride ≥ 500 mg/dL) than noncoronavirus disease 2019-associated acute respiratory distress syndrome (9 [33.3%] vs 1 [4.3%]; p = 0.014). Those with coronavirus disease 2019, compared with those without, received more propofol prior to becoming hypertriglyceridemic (median, 5,436.0 mg [interquartile range, 3,405.5–6,845.5 mg] vs 4,229.0 mg [interquartile range, 2,083.4–4,972.1 mg]; p = 0.027). After adjustment for propofol dose with logistic regression (odds ratio, 5.97; 95% CI, 1.16–59.57; p = 0.031) and propensity score matching (odds ratio, 8.64; 95% CI, 1.27–149.12; p = 0.025), there remained a significant difference in the development of hypertriglyceridemia between coronavirus disease 2019-associated acute respiratory distress syndrome and noncoronavirus disease 2019-associated acute respiratory distress syndrome. There was no difference between groups in time to hypertriglyceridemia (p = 0.063). Serum lipase was not different between those who did or did not develop hypertriglyceridemia (p = 0.545). No patients experienced signs or symptoms of pancreatitis. Conclusions: Patients with coronavirus disease 2019 acute respiratory distress syndrome experienced a higher rate of propofol-associated hypertriglyceridemia than noncoronavirus disease 2019 acute respiratory distress syndrome patients, even after accounting for differences in propofol administration.Keywords
This publication has 32 references indexed in Scilit:
- Impact of Ventilator Adjustment and Sedation–Analgesia Practices on Severe Asynchrony in Patients Ventilated in Assist-Control Mode*Critical Care Medicine, 2013
- Hypertriglyceridemia and Acute PancreatitisJAMA Internal Medicine, 2013
- Hypertriglyceridemia: a potential side effect of propofol sedation in critical illnessIntensive Care Medicine, 2012
- A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucosePancreatology, 2012
- Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational ResearchCommunications in Statistics - Simulation and Computation, 2009
- Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated PatientsJAMA, 2007
- Phenobarbital Provides Effective Sedation for a Select Cohort of Adult ICU Patients Intolerant of Standard Treatment: A Brief ReportHospital Pharmacy, 2006
- Propofol‐Associated Hypertriglyceridemia and Pancreatitis in the Intensive Care Unit: An Analysis of Frequency and Risk FactorsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Acute renal impairment in coronavirus-associated severe acute respiratory syndromeKidney International, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001